Literature DB >> 22135089

Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations.

Salvatore Petta1, Daniele Torres, Giovanni Fazio, Calogero Cammà, Daniela Cabibi, Vito Di Marco, Anna Licata, Giulio Marchesini, Alessandra Mazzola, Gaspare Parrinello, Salvatore Novo, Giuseppe Licata, Antonio Craxì.   

Abstract

UNLABELLED: There are contrasting results in studies of cardiovascular risk in patients with genotype 1 chronic hepatitis C (G1 CHC). We evaluated the prevalence of carotid atherosclerosis compared with a control population in order to assess the potential association between atherosclerosis, host and viral factors, and liver histological features. In all, 174 consecutive biopsy-proven G1 CHC patients were evaluated by anthropometric and metabolic measurements and 174 patients attending an outpatient cardiology unit were used as controls. Intima-media thickness (IMT) and carotid plaques, defined as focal thickening of >1.3 mm at the level of common carotid, were evaluated using ultrasonography. All G1 CHC biopsies were scored by one pathologist for staging and grading, and graded for steatosis. Carotid plaques were found in 73 (41.9%) G1 CHC patients compared with 40 (22.9%) control patients (P < 0.001). Similarly, G1 CHC patients had a greater IMT compared with control patients (1.04 ± 0.21 versus 0.90 ± 0.16; P < 0.001). Multivariate logistic regression analysis showed that older age (odds ratio [OR] 1.047, 95% confidence interval [CI]: 1.014-1.082, P = 0.005), and severe hepatic fibrosis (OR 2.177, 95% CI: 1.043-4.542, P = 0.03), were independently linked to the presence of carotid plaques. In patients ≤55 years, 15/67 cases with F0-F2 fibrosis (22.3%) had carotid plaques, compared with 11/21 (52.3%) with F3-F4 fibrosis (P = 0.008). By contrast, in patients >55 years the prevalence of carotid plaques was similar in those with or without severe fibrosis (25/43, 58.1% versus 22/43, 51.1%; P = 0.51).
CONCLUSION: Severe hepatic fibrosis is associated with a high risk of early carotid atherosclerosis in G1 CHC patients.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2012        PMID: 22135089     DOI: 10.1002/hep.25508

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  47 in total

Review 1.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

2.  Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study.

Authors:  Matteo Nicola Dario Di Minno; Pasquale Ambrosino; Antonio Riccardo Buonomo; Biagio Pinchera; Ilenia Calcaterra; Manuel Crispo; Riccardo Scotto; Francesco Borgia; Consalvo Mattia; Ivan Gentile
Journal:  Intern Emerg Med       Date:  2019-08-08       Impact factor: 3.397

3.  Chemoprevention for hepatocellular carcinoma: the role of statins.

Authors:  Giuseppe Cabibbo; Salvatore Petta; Calogero Cammà
Journal:  Hepatobiliary Surg Nutr       Date:  2013-02       Impact factor: 7.293

4.  Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women.

Authors:  Mark H Kuniholm; Xianhong Xie; Kathryn Anastos; Robert C Kaplan; Xiaonan Xue; Andrea Kovacs; Marion G Peters; Eric C Seaberg; Audrey L French; Mary A Young; Michael Augenbraun; Jeffrey A Martinson; Kristin A Bush; Alan L Landay; Howard D Strickler
Journal:  J Acquir Immune Defic Syndr       Date:  2014-11-01       Impact factor: 3.731

Review 5.  Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy.

Authors:  Diego García-Compeán; José Alberto González-González; Fernando Javier Lavalle-González; Emmanuel Irineo González-Moreno; Jesús Zacarías Villarreal-Pérez; Héctor J Maldonado-Garza
Journal:  Dig Dis Sci       Date:  2016-02       Impact factor: 3.199

6.  Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review.

Authors:  Evangelista Sagnelli; Caterina Sagnelli; Antonio Russo; Mariantonietta Pisaturo; Clarissa Camaioni; Roberta Astorri; Nicola Coppola
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Assessing cardiovascular risk in hepatitis C: An unmet need.

Authors:  Javier Ampuero; Manuel Romero-Gómez
Journal:  World J Hepatol       Date:  2015-09-08

8.  Risk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general population.

Authors:  L Kakinami; R C Block; M J Adams; S E Cohn; B Maliakkal; S G Fisher
Journal:  Int J Clin Pract       Date:  2013-01       Impact factor: 2.503

Review 9.  The hepatitis C virus infection as a systemic disease.

Authors:  Anna Linda Zignego; Laura Gragnani; Carlo Giannini; Giacomo Laffi
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

Review 10.  Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.

Authors:  Amedeo Lonardo; Luigi Elio Adinolfi; Luciano Restivo; Stefano Ballestri; Dante Romagnoli; Enrica Baldelli; Fabio Nascimbeni; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.